Comparison of Substance Use Screeners in Assessing Prescription Drug Abuse and Other Illicit Drug Use among Pregnant Women

药物使用筛查仪在评估孕妇处方药滥用和其他非法药物使用方面的比较

• 批准号: 9762358
• 负责人: Victoria Hope Coleman-Cowger
• 金额: $ 16.9万
• 依托单位: THE EMMES COMPANY, LLC
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-15 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9762358
• 关键词: Comparison; Substance; Use; Screeners; Assessing

Project Summary Over the last 3 decades, use of prescription drugs has increased by more than 60%, and prevalence of prescription drug use among pregnant women is currently estimated around 50%. Children born to women who abuse prescription medications are more likely to be born with neonatal abstinence syndrome, the incidence of which has doubled in the past 5 years. Recent national survey data show that the rate of current illicit drug use is 14.6% among pregnant adolescents, 8.6% among young adults, and 3.2% among adults. The first step in identifying both prescription drug abuse and illicit drug use during pregnancy is screening; however, no specific substance use screener has been recommended for use with pregnant women to identify illicit or prescription drug use. The proposed study will compare and validate three existing substance use screeners - 4 P's Plus, NIDA Quick Screen, and the Substance Use Risk Profile-Pregnancy scale - among at least 500 pregnant women in all three trimesters of pregnancy presenting to two primary care clinics in Baltimore over 1 year. Specific aims are to: (1) conduct validity analyses to determine sensitivity, specificity, usability, and how each scale compares to the others and to the gold standard of urine drug testing in identifying prescription and illicit drug use; (2) determine the impact of clinic population variables (age, race, trimester of pregnancy) on validity of the three substance use screeners; and (3) assess birth outcomes (birth weight, gestational age, head circumference, and NICU admissions) associated with the most widely used prescription drug. The end goal of the study is to determine which screening tool(s) is most effective in identifying prescription drug abuse and illicit drug use among pregnant women, utilizing urine drug testing as the gold standard to designate use and electronic medical records (EMR) as a supplement to identify prescribed drugs. Aim 3 was added to capture the important and relevant associations between the most widely used prescription drug and birth outcomes.

项目摘要 在过去的30年里，处方药的使用增加了60%以上， 据估计，目前孕妇使用处方药的比例约为50%。妇女所生子女， 滥用处方药者更容易患有新生儿禁欲综合征， 在过去五年里翻了一番。最近的国家调查数据表明，目前非法药物使用率 在怀孕少女中为14.6%，在年轻人中为8.6%，在成年人中为3.2%。的第一步 识别处方药滥用和怀孕期间非法药物使用是筛查;然而，没有具体的 物质使用筛选器已被推荐用于孕妇，以确定非法或处方 吸毒拟议的研究将比较和验证三个现有的物质使用筛选- 4 P的加， NIDA快速筛查和物质使用风险概况-妊娠量表-在至少500名孕妇中 在巴尔的摩的两个初级保健诊所就诊超过1年的所有三个孕期的妇女。 具体目标是：（1）进行有效性分析，以确定敏感性，特异性，可用性，以及如何每一个 规模相比，其他和黄金标准的尿液药物检测，以确定处方和非法 药物使用;（2）确定临床人群变量（年龄、种族、妊娠期）对有效性的影响 三个物质使用筛查;和（3）评估出生结果（出生体重，胎龄，头 周长和NICU入院）与最广泛使用的处方药相关。的最终目标 该研究旨在确定哪种筛查工具在识别处方药滥用方面最有效， 孕妇非法药物使用情况，利用尿液药物检测作为确定使用情况的金标准， 电子病历（EMR）作为补充，以确定处方药。目标3被添加到捕获 最广泛使用的处方药和出生结果之间的重要和相关关联。

项目成果

Patient Perceptions of Three Substance Use Screening Tools for Use During Pregnancy.

患者对怀孕期间使用的三种药物使用筛查工具的看法。

• DOI: 10.1007/s10995-022-03442-1
• 发表时间: 2022
• 期刊: Maternal and child health journal
• 影响因子: 2.3
• 作者: Trocin,KathleenE;Oga,EmmanuelA;Mulatya,Caroline;Mark,KatrinaS;Coleman-Cowger,VictoriaH
• 通讯作者: Coleman-Cowger,VictoriaH

Prevalence and associated birth outcomes of co-use of Cannabis and tobacco cigarettes during pregnancy.

• DOI: 10.1016/j.ntt.2018.06.001
• 发表时间: 2018-07
• 期刊: Neurotoxicology and teratology
• 影响因子: 2.9
• 作者: Coleman-Cowger VH;Oga EA;Peters EN;Mark K
• 通讯作者: Mark K

Prenatal Substance Use and Perceptions of Parent and Partner Use Using the 4P's Plus Screener.

使用 4Ps Plus 筛查仪了解产前药物使用情况以及父母和伴侣使用药物的看法。

• DOI: 10.1007/s10995-018-2647-2
• 发表时间: 2019
• 期刊: Maternal and child health journal
• 影响因子: 2.3
• 作者: Oga,EmmanuelA;Peters,EricaN;Mark,Katrina;Trocin,Kathleen;Coleman-Cowger,VictoriaH
• 通讯作者: Coleman-Cowger,VictoriaH